NCT06585410 2026-04-08
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 3 Recruiting
Clinical Trials
16 trialsNCT04657991 2026-04-07
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Pfizer
Phase 3 Active not recruiting
NCT05727904 2026-04-03
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Iovance Biotherapeutics, Inc.
Phase 3 Recruiting
NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT02967692 2025-09-18
COMBI-i
Novartis
Phase 3 Terminated
NCT05608291 2025-05-13
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT05297565 2025-02-27
CheckMate-6GE
Bristol-Myers Squibb
Phase 3 Completed
NCT04410445 2023-04-21
PIVOT-12
Nektar Therapeutics
Phase 3 Terminated
NCT03445533 2022-11-08
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Idera Pharmaceuticals, Inc.
Phase 3 Terminated
NCT03329846 2021-07-09
An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
Bristol-Myers Squibb
Phase 3 Completed
NCT01763164 2021-03-22
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Pfizer
Phase 3 Completed
NCT00039000 2012-09-07
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
Agenus Inc.
Phase 3 Completed
NCT00434057 2012-02-14
Evaluation of Pigmented Skin Lesions With MelaFind(R) System
MELA Sciences, Inc.
Phase 3 Completed
NCT00518895 2011-11-07
AGENDA
Genta Incorporated
Phase 3 Completed
NCT00094653 2011-07-11
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Bristol-Myers Squibb
Phase 3 Completed
NCT00003647 2008-07-25
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
Vical
Phase 3 Completed